Fluor

FLR

Capitalización de mercado USD 6279 M

Here is how Fluor (FLR) and Legence (LGN) have performed compared to their sector so far this year.

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) will hold a conference call to review results for its third quarter ended September 30, 2026. The public is invited to listen to the conference call on Friday, November 6, 2026, at 8:30 a.m. Eastern with Chief Executive Officer Jim Breuer and Chief Financial Officer John Regan. Financial results will be released prior to the market open that day. The live webcast and a reply will be available with accompanying slides online at invest.

FLR's JGC joint venture will execute LNG Canada Phase 2, with Fluor set to recognize a $7.5 billion share as production capacity is poised to double.

SHEL greenlights LNG Canada Phase 2, doubling capacity to 28 mtpa and securing nearly 6 mtpa of additional LNG from the project.

The owners and operators of commercial reactors in the U.S. are planning for a larger and longer-lasting fleet. A recent survey of utility companies from the Nuclear Energy Institute (NEI) highlights rising interest in new reactors and expectations for operating lives beyond 80 years.

Here is how Fluor (FLR) and Owens Corning (OC) have performed compared to their sector so far this year.

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

CALGARY, Alberta — September 10 , 2026 — Leads & Copy — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF), a Canadian company focused on developing pharmaceutical-grade barium and iodine contrast media for medical imaging, has achieved its first milestone under a non-dilutive Collaboration and Funding Agreement with Bayer AG. The company announced that it successfully submitted a complete feasibility work plan and timetable, which has been approved by Bayer. The milestone achievement triggers the first major non-dilutive payment of USD $1,000,000 from Bayer. This payment, combined with the initial USD $350,000 received on March 31, 2026, brings the total funding received by Voyageur from Bayer to USD $1,350,000 of the committed USD $2,350,000.

CALGARY, Alberta – TheNewswire - September 9, 2026 – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“ Voyageur ” or the “ Company ”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has achieved the first milestone under its non-dilutive Collaboration and Funding Agreement with Bayer AG (“ Bayer ”) dated February 10, 2026 (the  “ Agreement ”) by submitting a complete feasibility work plan and timetable which has been approved by Bayer. (Collaboration funding news https://finance.yahoo.com/news/voyageur-pharmaceuticals-announces-collaboration-bayer-144926270.html )

Investors usually focus on reactor developers and uranium miners when deciding on allocations for investing in the nuclear renaissance. A narrow view on the nuclear sector could result in missed opportunities for investment returns in nuclear-adjacent companies.